Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hearing On Natco Plea To Make Generic Version Of Roche, Pfizer Cancer Drugs Extended To March

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - An Indian patent office hearing on the closely watched application by Hyderabad, India-based Natco Pharma for a compulsory license to sell generic copies of Roche and Pfizer drugs to poor countries will continue next month, a spokesman for the patent office said
Advertisement

Related Content

Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs
India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs
Thai FDA Head “Surprised” By Health Minister’s Decision To Remove Him From Post – PharmAsia News Interview
Testing Times For India’s Drug Patent Law
Advertisement
UsernamePublicRestriction

Register

SC068049

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel